Luteinizing hormone
Also known as: hMG (partial LH activity), Interstitial cell-stimulating hormone (ICSH), LH, lutropin, Lutropin alfa, Luveris, Menopur, r-hLH, recombinant human LH
Source Luteinizing hormone at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Luteinizing hormone (LH) is a prescription glycoprotein hormone used in assisted reproductive technologies to stimulate ovarian follicle development and testosterone production. It is administered by injection (intramuscular or subcutaneous) and is often combined with follicle‑stimulating hormone (FSH) in protocols for in‑vitro fertilisation (IVF) and other fertility treatments.
Mechanism of Action
LH binds to the luteinizing hormone receptor, a G‑protein‑coupled receptor on ovarian theca cells and testicular Leydig cells. Receptor activation raises intracellular cAMP, triggering enzymes that convert cholesterol to androgens (e.g., testosterone) and, in the ovary, supports the final steps of follicle maturation and ovulation. Recombinant LH mimics this natural signalling cascade.
What the Research Shows
Systematic reviews and meta‑analyses of IVF cycles show that adding recombinant LH to FSH does not consistently improve clinical pregnancy or live‑birth rates compared with FSH alone. In progestin‑primed ovarian stimulation (PPOS) protocols, which suppress the natural LH surge with progesterone, the LH surge rate was markedly lower and ovarian hyperstimulation syndrome was reduced, suggesting a role for LH regulation. Trials of resveratrol in PCOS reported a modest reduction in circulating LH levels, indicating that LH can serve as a biomarker of treatment response. Overall, the evidence does not support a universal benefit of routine LH supplementation, and its impact appears context‑dependent.
Reported Benefits
When used as part of a combined gonadotropin regimen, LH can help achieve adequate steroidogenesis and follicular development, particularly in patients with low endogenous LH. In PPOS protocols, controlling the LH surge reduces premature ovulation and lowers the risk of ovarian hyperstimulation syndrome. LH measurement also provides a useful indicator of therapeutic response in conditions such as PCOS.
Limitations of the Evidence
Large meta‑analyses have found no clear advantage of adding LH to FSH for improving pregnancy or live‑birth outcomes, and the benefit may be limited to specific sub‑groups. Evidence is heterogeneous, with varying definitions of advanced maternal age and ovarian reserve, making it difficult to generalise findings. Direct safety data on recombinant LH are sparse in the cited literature, and most studies focus on protocol comparisons rather than isolated LH effects.
Safety Considerations
The IVF studies that evaluated LH addition did not report specific adverse events, indicating that short‑term use appears well tolerated. However, the abstracts provide limited safety information, and rare or long‑term effects have not been characterised. Clinicians should monitor patients for typical gonadotropin‑related reactions such as injection site irritation, ovarian enlargement, or hormonal imbalances.
How It Is Administered
Recombinant LH is supplied for injection and can be given either intramuscularly or subcutaneously. It is typically mixed with FSH in a single syringe or administered sequentially, depending on the chosen stimulation protocol. No oral or topical formulations are described in the cited sources.
Routes of Administration
Goals & Uses
- Male hypogonadism / testosterone deficiencyMale Reproductive HealthModerate
- Induction of ovulationReproductiveHigh
- Induction of follicular development in LH-deficient womenReproductive Endocrinology / FertilityHigh
- Spermatogenesis induction in hypogonadotropic hypogonadismMale FertilityModerate
- Assisted reproductive technology (ART) stimulationReproductive Endocrinology / FertilityHigh
- Support testosterone production in menEndocrineModerate
- Triggering ovulation / luteinizationReproductive EndocrinologyHigh
Contraindications
- Primary ovarian failure / primary hypogonadismEndocrineHigh
- Hormone-sensitive tumors (e.g., ovarian, uterine, testicular cancer)OncologyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to gonadotropins or excipientsAllergy/ImmunologyHigh
- Estrogen-dependent neoplasmsOncologyHigh
- Ovarian cysts or enlarged ovaries (not due to PCOS)ReproductiveModerate
- Uncontrolled thyroid or adrenal dysfunctionEndocrinologyModerate
- Uncontrolled hypertensionCardiovascularModerate
Adverse Effects
- Injection site reactionsLocalCommon
- Multiple gestationReproductiveUncommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicCommonPain in the head or upper neck
- Ovarian hyperstimulation syndromeReproductive / EndocrineUncommon
- Ectopic pregnancyReproductive / ObstetricRare
- Abdominal pain / bloatingGastrointestinalCommon
- Ovarian hyperstimulation syndrome (OHSS)ReproductiveUncommon
Drug Interactions
- Human Chorionic Gonadotropin (hCG)Moderate
- GnRH agonists (e.g., leuprolide, buserelin)Low
- Recombinant FSH (follitropin alfa/beta)Low
- GnRH antagonists (e.g., cetrorelix, ganirelix)Low
- GnRH agonistsModerate
Population Constraints
- Women with polycystic ovary syndrome (PCOS)Endocrine / ReproductiveRelative
- Pediatric patientsAgeRelative
- Prepubertal individualsPediatricAbsolute
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionApprovedApproved: infertility in womenAvailable as recombinant LH.
- United StatesApprovedApproved: infertility in women, hypogonadotropic hypogonadism in menApproved as recombinant LH (e.g., lutropin alfa).
- United KingdomApprovedApproved: Stimulation of follicular development in LH and FSH-deficient women in combination with FSHApproved by MHRA post-Brexit; Luveris retains authorization in the UK
Lutropin alfa (Luveris) is EMA- and FDA-approved for stimulation of follicular development in LH-deficient women. Urinary-derived gonadotropin combinations containing LH activity (e.g., Menopur, hMG) are also approved. Recombinant LH is classified as a prescription biological product in most jurisdictions.
Evidence & Sources
- Journal ArticleHighAli Fadlalmola H, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleHighHuijben M, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleHighGaner Herman H, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighGuan S, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighConforti A, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighHuijben M, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
When is recombinant LH added to an IVF stimulation protocol?
LH is usually added when a patient has low endogenous LH, a poor response to FSH alone, or when the clinician wishes to optimise steroidogenesis. Current meta‑analyses suggest that routine addition does not improve outcomes, so its use is individualized.
Does LH increase the risk of ovarian hyperstimulation syndrome (OHSS)?
In the progestin‑primed ovarian stimulation protocol, which suppresses the LH surge, the incidence of OHSS was lower. The data do not show a direct link between LH supplementation and higher OHSS risk, but careful dosing is advised.
Can LH be used to treat male infertility?
LH itself is not used as a primary therapy for men. Studies on clomiphene citrate show that raising endogenous LH can improve semen parameters, but the abstracts do not provide evidence for direct LH administration in male patients.
Is LH therapy safe for women with polycystic ovary syndrome (PCOS)?
The PCOS study measured LH levels rather than administering LH. It found that lowering LH with resveratrol correlated with clinical improvement, but no safety data on exogenous LH in PCOS were presented.
What form of LH is available for clinical use?
The approved product is recombinant LH (e.g., Luveris), supplied as a sterile injectable solution for intramuscular or subcutaneous use. It is prescribed by specialists in reproductive endocrinology.
What is Luteinizing hormone?
Luteinizing hormone (LH) is a prescription glycoprotein hormone used in assisted reproductive technologies to stimulate ovarian follicle development and testosterone production. It is administered by injection (intramuscular or subcutaneous) and is often combined with follicle‑stimulating hormone (FSH) in protocols for in‑vitro fertilisation (IVF) and other fertility treatments.
What is Luteinizing hormone used for?
Luteinizing hormone is educationally associated with: Male hypogonadism / testosterone deficiency, Induction of ovulation, Induction of follicular development in LH-deficient women, Spermatogenesis induction in hypogonadotropic hypogonadism, Assisted reproductive technology (ART) stimulation, Support testosterone production in men, Triggering ovulation / luteinization. Educational only — not medical advice.
How is Luteinizing hormone administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Luteinizing hormone?
Reported adverse effects include: Injection site reactions, Multiple gestation, Injection site pain, Headache, Ovarian hyperstimulation syndrome, Ectopic pregnancy, Abdominal pain / bloating, Ovarian hyperstimulation syndrome (OHSS). This list is not exhaustive — consult a qualified clinician.
Who should avoid Luteinizing hormone?
Recorded contraindications: Primary ovarian failure / primary hypogonadism, Hormone-sensitive tumors (e.g., ovarian, uterine, testicular cancer), Pregnancy, Hypersensitivity to gonadotropins or excipients, Estrogen-dependent neoplasms, Ovarian cysts or enlarged ovaries (not due to PCOS), Uncontrolled thyroid or adrenal dysfunction, Uncontrolled hypertension. Consult a qualified clinician before use.